Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
This article was originally published in PharmAsia News
Executive Summary
Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.
You may also be interested in...
Pharma Continues Its March To Academia, as Sanofi, UCB Strike Deals
In two very different collaborations, Sanofi teams up with Weill Cornell professor to screen for TB drug candidates, while UCB initiates its first project under a strategic research alliance with Harvard.
Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO
Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.
MagGenome On Path To Nanoparticle Adjuvant, Founder Seeks Investment Opportunities
MagGenome, an Indian biotech which develops nanoparticle-based products, is in the early stage of research for a vaccine adjuvant. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the promise of nanotechnology and the environment in India for cell and gene therapies, among other topics, in this wide-ranging audio interview.